Development of antibody-based c-Met inhibitors for targeted cancer therapy

Development of antibody-based c-Met inhibitors for targeted cancer therapy

Dongheon Lee, Eun-Sil Sung, Jin-Hyung Ahn, Sungwon An, Jiwon Huh, Weon-Kyoo You Hanwha Chemical R&D Center, Biologics Business Unit, Daejeon, Republic of Korea Abstract: Signaling pathways mediated by receptor tyrosine kinases (RTKs) and their ligands play important roles in the development...

Full description

Bibliographic Details
Main Authors:	Lee D, Sung ES, Ahn JH, An S, Huh J, You WK
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-02-01
Series:	ImmunoTargets and Therapy
Subjects:	Hepatocyte growth factor Ligands Receptor tyrosine kinase Signaling pathway Therapeutic agent
Online Access:	https://www.dovepress.com/development-of-antibody-based-c-met-inhibitors-for-targeted-cancer-the-peer-reviewed-article-ITT

Similar Items

Control of cell death/survival balance by the MET dependence receptor
by: Leslie Duplaquet, et al.
Published: (2020-02-01)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
by: Chen-Yu Hu, et al.
Published: (2019-12-01)

Role of Met Axis in Head and Neck Cancer
by: Yiru Xu, et al.
Published: (2013-11-01)

MET Oncogene Controls Invasive Growth by Coupling with NMDA Receptor
by: Simona Gallo, et al.
Published: (2022-09-01)

Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
by: Sareshma Sudhesh Dev, et al.
Published: (2021-11-01)

Reduced HGF/MET Signaling May Contribute to the Synaptic Pathology in an Alzheimer's Disease Mouse Model
by: Jing Wei, et al.
Published: (2022-07-01)

Exploring receptor tyrosine kinases-inhibitors in Cancer treatments
by: D. Samuel Metibemu, et al.
Published: (2019-12-01)

Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia
by: Kalpana K. Bhanumathy, et al.
Published: (2021-01-01)

The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models
by: Friedhelm Bladt, et al.
Published: (2014-08-01)

Physiological Signaling and Structure of the HGF Receptor MET
by: Gianluca Baldanzi, et al.
Published: (2014-12-01)

The Interference between SARS-CoV-2 and Tyrosine Kinase Receptor Signaling in Cancer
by: Oana-Stefana Purcaru, et al.
Published: (2021-05-01)

AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
by: Chenjing Zhu, et al.
Published: (2019-11-01)

Targeting Protein Kinases and Epigenetic Control as Combinatorial Therapy Options for Advanced Prostate Cancer Treatment
by: Soghra Bagheri, et al.
Published: (2022-02-01)

Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
by: Lucia Demkova, et al.
Published: (2018-02-01)

Activated HGF-c-Met Axis in Head and Neck Cancer
by: Levi Arnold, et al.
Published: (2017-12-01)

MET in glioma: signaling pathways and targeted therapies
by: Fangling Cheng, et al.
Published: (2019-06-01)

MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)‐dependent oncogenic driver in vitro and in humanised HGF knock‐in mice
by: Marie Fernandes, et al.
Published: (2023-11-01)

Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products
by: Kodappully S. Siveen, et al.
Published: (2018-02-01)

Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors
by: Wagner Ricardo Montor, et al.
Published: (2018-02-01)

Phage-Displayed Peptides for Targeting Tyrosine Kinase Membrane Receptors in Cancer Therapy
by: Annamaria Aloisio, et al.
Published: (2021-04-01)

Functional selectivity of Receptor Tyrosine Kinases regulates distinct cellular outputs
by: Sakim S. Samad, et al.
Published: (2024-01-01)

Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer
by: Mai Tanaka, et al.
Published: (2021-09-01)

Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma
by: Sicong Wang, et al.
Published: (2023-02-01)

HGF/SF Increases Tumor Blood Volume: A Novel Tool for the In Vivo Functional Molecular Imaging of Met
by: Galia Tsarfaty, et al.
Published: (2006-05-01)

GTN057, a komaroviquinone derivative, induced myeloma cells' death in vivo and inhibited c‐MET tyrosine kinase
by: Mikio Okayama, et al.
Published: (2023-04-01)

Receptor tyrosine kinases and schistosome reproduction: new targets for chemotherapy
by: Marion eMorel, et al.
Published: (2014-07-01)

HGF/Met Axis in Heart Function and Cardioprotection
by: Simona Gallo, et al.
Published: (2014-10-01)

Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors
by: Edward Greenfield, et al.
Published: (2014-12-01)

Recording and classifying MET receptor mutations in cancers
by: Célia Guérin, et al.
Published: (2024-04-01)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
by: Paula Aldaz, et al.
Published: (2021-11-01)

AXL/Gas6 signaling mechanisms in the hypothalamic-pituitary-gonadal axis
by: Pardis Mohammadzadeh, et al.
Published: (2023-06-01)

pYtags enable spatiotemporal measurements of receptor tyrosine kinase signaling in living cells
by: Payam E Farahani, et al.
Published: (2023-05-01)

Therapeutic potential of tyrosine-protein kinase MET in osteosarcoma
by: Ming Zeng, et al.
Published: (2024-03-01)

Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
by: Manali Tilak, et al.
Published: (2021-02-01)

The Spectrum of Molecular Pathways in Gliomas—An Up-to-Date Review
by: Reinhold Nafe, et al.
Published: (2023-08-01)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
by: Lorenzo-Vizcaya A, et al.
Published: (2020-06-01)

Novel Peptide CM 7 Targeted c-Met with Antitumor Activity
by: Chunlei Xia, et al.
Published: (2020-01-01)

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer
by: Dantong Sun, et al.
Published: (2023-02-01)

PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models
by: Lluís Nisa, et al.
Published: (2017-05-01)

Dimer Interface in Natural Variant NK1 Is Dispensable for HGF-Dependent Met Receptor Activation
by: Yumiko Tahira, et al.
Published: (2021-08-01)